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Abstract: Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the
myocardium associated to mutations in sarcomeric genes, but the link between genotype and
phenotype remains poorly understood. Magnetic resonance spectroscopy studies have demonstrated
impaired cardiac energetics in patients with HCM, and altered mitochondria were described in
biopsies, but little is known about possible perturbations of mitochondrial function and adenosine
triphosphate (ATP) production/consumption. The aim of this study was to investigate possible
abnormalities in mitochondrial enzymes generating/scavenging reactive oxygen species, and changes
in the Ca2+-activated ATPases in myocardial tissue from patients with obstructive HCM undergoing
surgical myectomy compared to unused donor hearts (CTRL). Methods and Results: Both the
amount and activity of mitochondrial Complex I (nicotinamide adenine dinucleotide -reduced form,
NADH, dehydrogenase) were upregulated in HCM vs. CTRL, whilst the activity of Complex V (ATP
synthase) was not reduced and ATP levels were significantly higher in HCM vs. CTRL. Antioxidant
Mn-activated superoxide dismutase (SOD2) and (m)-aconitase activities were increased in HCM vs.
CTRL. The Cu/Zn-activated superoxide dismutase (SOD1) amount and mtDNA copy number were
unaltered in HCM. Total Ca2+-activated ATPase activity and absolute amount were not different HCM
vs. CTRL, but the ratio between ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting type
2 (ATP2A2) and type 1 (ATP2A1), ATP2A2/ATP2A1, was increased in HCM in favor of the slow
isoform (ATP2A2). Conclusion: HCM is characterized by mitochondrial Complex I hyperactivity
and preserved Ca2+-activated ATPase activity with a partial switch towards slow ATP2A2. This data
may give insight into the abnormal cellular energetics observed in HCM cardiomyopathy but other
studies would need to be performed to confirm the observations described here.
Keywords: obstructive hypertrophic cardiomyopathy (HCM); mitochondrial energetics;
mitochondrial Complex I (NADH dehydrogenase); mitochondrial Complex V (ATP synthase);
reactive oxygen species (ROS) scavenger enzymes; Ca2+-activated ATPase
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1. Introduction
Hypertrophic cardiomyopathy (HCM) is the most common cardiac genetic disease, characterized
by an extremely variable clinical phenotype. More than 1400 mutations have been identified, mostly in
genes encoding for sarcomeric proteins [1]. Mutation can be demonstrated in approximately 60% of
HCM patients and are considered causative [2,3]. A common cellular phenotype induced by HCM
sarcomere mutations is an inefficient sarcomere contraction, which is attributed to diverse changes in
sarcomere properties including increased myofilament Ca2+ sensitivity and triphosphatase (ATPase)
activity suggesting increased adenosine triphosphate (ATP) utilization [4]. This is consistent with
in vivo studies using 31P-magnetic resonance (MR) spectroscopy that have demonstrated impaired
cardiac energetics under resting conditions and during exercise in patients with HCM [5–8].
The ATPases are regulators of both mitochondrial and sarcoendoplasmic reticulum Ca2+ pumps.
Mitochondria directly communicate with sarcoendoplasmic reticulum via a redox signaling interface [9].
Many of the sarcoendoplasmic reticulum mitochondrial Ca2+/transporters and signaling proteins are
sensitive to redox regulation and are directly exposed to the reactive oxygen species (ROS), oxidative
phosphorylation (OXPHOS) by-products that have sensors at the redox signaling interface. Variations
in mitochondrial fission and size [10] have been described in biopsies from patients with HCM [11]
and oxidative stress-related elevation of 4-hydroxy-2-nonenal (HNE)-modified protein has been shown
in the myocardium of HCM patients with left ventricular (LV) systolic dysfunction [12]. Little is
known about possible perturbations in mechanisms controlling mitochondrial function and ATP
production/consumption [13].
Studies in mutant animal models of HCM support a mitochondrial contribution to some of the
heterogeneity of the disease phenotype. Mutant mice at prehypertrophic stage showed preserved
mitochondrial function, stimulation of nicotinamide adenine dinucleotide-reduced form (NADH)
generation, which fuels respiration and ATP. Conversely a reduction in OXPHOS complex activities
was describe in end-stage mice [14,15] Taken together these findings suggested that a hypermetabolic
mitochondrial state precedes development of the cardiomyopathy in mice.
Aim of the present study was to ascertain whether there are abnormalities in mitochondrial
enzymes associated with changes in the Ca2+-activated ATPases in myocardial tissue from patients
with obstructive HCM undergoing surgical myectomy compared to unused donor hearts.
2. Methods
Patients with obstructive HCM, diagnosed according to guidelines [16], were prospectively
studied and a cohort, selected for surgical myectomy, of therapeutic option in-patients with significant
subaortic gradients [17] was enrolled. Inclusion criteria were: unequivocal diagnosis of HCM
according to existing guidelines [16] with maximum LV wall thickness ≥ 1.5 cm, age > 18 years,
sinus rhythm, presence of severe resting or inducible LV outflow tract obstruction (peak gradient
≥ 50 mmHg), and clinical indication for surgical myectomy, such as the presence of advanced
heart failure symptoms (NYHA Class ≥ III), syncope or presyncope due to LV obstruction, exercise
hypotension, drug-refractory symptoms, as well as the presence of moderate-to-severe systolic anterior
motion-related mitral regurgitation. Exclusion criteria included coronary artery disease, aortic valve
stenosis and uncontrolled arterial hypertension (mmHg >140 systolic and/or >90 diastolic) [18].
At surgery, myectomies from the interventricular septum were harvested.
Hearts from unused donors, i.e., discarded from transplantation because of noncardiac technical
reasons (e.g., suitable recipient unavailability), were collected at the department of oncological and
pathological sciences at Sapienza University (Rome, Italy) and served as controls (CTRL). According to
the Italian law, CTRL hearts were provided anonymously, the donors’ age was <60 years, and no data
about them were supplied.
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2.1. Sample Processing and Histology
Myectomies, harvested immediately during surgery, were cut into 2 mm-thick slices
perpendicularly to the endocardium within two hours from collection. Slices were embedded
in Killik (BioOptica, Milan, Italy), and frozen in 2-methyl butane/liquid N2 (for confocal analysis and
LCM) or snap-frozen in N2 (for proteins and mRNA extraction), or processed for paraffin inclusion.
Paraffin blocks were cut and at least two sections were stained with hematoxylin/eosin and
Azan–Mallory trichrome stains. Patient biopsies were examined for the presence of the pathologic
hallmarks of HCM, i.e., myocyte hypertrophy and disarray, expansion of the interstitial collagen
compartment and replacement fibrosis, wall thickening by intimal and medial smooth muscle cell
hyperplasia in intramyocardial arteries and narrowing of myocardial capillaries [19].
CTRL biopsies were obtained and processed within two hours from the explant examined under
light microscope, to exclude the presence of cardiomyocyte hypertrophy, necrosis or degenerative
changes, significant fibrosis, or inflammatory infiltrates.
Serial cryosections (5, 10, or 20 µm thick depending on type of assay) were obtained by a Leica
CM1850 cryostat (Leica Microsystems GmbH, Wetzlar, Germany) from frozen slices collected onto
slides or in vials for subsequent use.
Blood samples (10 mL) from patients with HCM and from a group of healthy volunteers (n = 11)
were withdrawn in EDTA tubes and processed to obtain plasma.
2.2. Genetic Testing
Total DNA was extracted from cryosections (kit ID: 69504, Qiagen, Hilden, DE) and 26 genes
were analyzed (Supplementary Table S1) by next generation sequencing with MiSeq System (Illumina,
San Diego, CA). Variants were classified following guidelines [20] using Cardio-Classifier [21] or
InterVar [22].
2.3. NADH Dehydrogenase Histochemistry
Frozen sections (5µm thick) were air-dried, rinsed in phosphate-buffered saline (PBS) 0.05 M pH 7.4
for 5 min at room temperature, then transferred to 1 mM NADH/0.2 mM Nitroblue Tetrazolium/100 mM
Tris-HCl buffer pH 8.0 containing 0.2% Triton X-100 solution for a maximum of 1 h at 37 ◦C to allow
the oxidation of NADH and the formation of a stable blue formazan. The reaction was stopped by
rinsing the sections in PBS. The sections were analyzed using an Eclipse 55i microscope equipped with
a DS-L1 camera (Nikon, Tokyo, Japan) [23,24].
The absence of an artifactual signal in the absence of the substrate in the reaction mixture has been
verified (Supplementary Figure S1). Optical density of the blue formazan signal was assessed by FiJi
software. At least 10 fields from 10× images were analyzed. In these fields the cardiomyocytes areas
were selected as regions of interest where the average intensity of signal was measured and normalized
versus the area of the region. Interstitium and arteries/arterioles were excluded from the measure.
2.4. Quantification of Mitochondrial DNA
Total DNA was extracted from myocardial tissue using the Wizard Genomic DNA purification
kit (Promega, Madison, WI, USA). Absolute quantification of mitochondrial DNA was performed by
quantitative real-time polymerase chain reaction (PCR) as previously described [25].
2.5. Enzyme-Linked Immunosorbent Assay (ELISA)
Tissue amounts of cardiac ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting type 1
(ATP2A1) and type 2 (ATP2A2) were quantified in protein extracts from HCM and CTRL by specific
competitive ELISA (MBS919218, MBS7252760, MyBioSource Inc., San Diego, CA, USA), following the
manufacturer’s instructions.
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Enzymatic activity of both Cu/Zn-activated superoxide dismutase (SOD1) and Mn-activated
superoxide dismutase (SOD2) was determined in freshly prepared tissue homogenate supernatants and
pellets, respectively, by a colorimetric activity assay determining the conversion of xanthine oxidase
to superoxide in the presence of a substrate, with formation of a colored product to read at 450 nm
(EIASODC, Life Technologies Corporation, Carlsbad, CA, USA). Quantification was performed using a
standard curve generated with bovine erythrocyte SOD standard.
The activity of mitochondrial (m-)aconitase (conversion of citrate into isocitrate, then to a colored
product with a maximum absorbance at 450 nm), the amount of NADH dehydrogenase (sandwich
assay, with HeLa cell extract for standard curve) and of ATP synthase (assay designed for cell/tissue
lysates, using a capture antibody specific for human ATP synthase, and for measures at 600 nm) were
determined by ELISA (ab83459, ab178011, ab124539, all from Abcam, Cambridge, UK). Measurements
were performed on an Infinite F200 microplate reader (TECAN Group Ltd., Männedorf, Switzerland).
Samples were run in triplicate.
2.6. Mitochondrial Complex I and ATP Assays
Mitochondrial Complex I activity was determined by a colorimetric assay (ab109721, Abcam)
in mitochondria isolated from frozen myocardial tissues immediately before the test (Mitochondria
isolation kit for tissues, ab110168, Abcam). The assay was based on the oxidation of NADH to NAD+
and on the simultaneous reduction of a dye, leading to increased absorbance at OD = 450 nm.
ATP content was determined in freshly collected and prepared protein extracts from snap-frozen
tissues. (ATP Determination Kit, Molecular Probes, Eugene, OR) as previously described [26]. The assay is
based on luciferase requirement for ATP in producing light (emission maximum ~560 nm at pH 7.8).
Samples were run in triplicate and luminescence was measured on a Mitras LB 940 (Berthold, Bad
Wildbad, Germany).
2.7. ATPase (Fast/Slow) Histochemistry
To visualize fast- and slow-ATPase activities of cardiac cells, two series of unfixed cryosections
(5 µm thick) were treated. The assay is based on the different sensitivity of slow/fast ATPase to
pH [27,28]. Acid preincubation in 0.1 M sodium acetate buffer at pH 4.6 (10 min at 4 ◦C) in the presence
of 10 mM ETDA inhibited the fast ATPase activity in a series of slides, while the other was incubated
with 0.1 M sodium acetate buffer. All the slides were successively incubated in 0.5 mg/mL ATP in 0.1 M
sodium acetate buffer at pH 9.4 (11 min at 37 ◦C), then treated with 2% COCl2 for 5 min. Upon rinsing in
distilled water, the sections were differentiated in ammonium sulfide for 30s to obtain a brownish-black
precipitate of cobalt sulfide. Intensity of the color is associated to activity. The background signal
in the absence of ATP in the reaction mixture was verified. (Supplementary Figure S2). Glycerin
jelly-mounted sections were analyzed under Eclipse 55i microscope equipped with a DS-L1 camera
(Nikon, Tokyo, Japan).
2.8. ATPase and Cardiac Muscle Creatine Kinase Activities
Ca2+-activated ATPase was evaluated in tissue extracts enriched in myosins [29]. The hydrolysis
of inorganic phosphate was measured by spectroscopy [30,31] according to Myosin-ATPase protocol
by Sigma-Aldrich. Briefly, tissue protein extracts were obtained and incubated in 200 nM glycine buffer
containing 100 mM CaCl2 and 50 mM ATP (5 min, room temperature) followed by 10% (NH4)2MoO4 in
H2SO4 solution containing FeSO4. Phosphorus solution was used in the standard curve. Absorbance
was read after five minutes at 660 nm on an Ultrospec2100pro (GE Healthcare-Amersham Biosciences,
Little Chalfont, UK).
The activity of cardiac muscle creatine kinase (CK-MB) was measured in freshly prepared extracts
by a colorimetric assay (68CL-CK-S100, RayBiotech Inc., Peachtree Corners, GA, USA) based on the
conversion of creatine to phosphocreatine in the presence of ATP and of a probe. Samples were run in
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triplicate. The probe’s colored product was read at 450 nm on an Infinite F200 microplate reader and
quantified following manufacturer’s instructions.
2.9. Statistical Analysis
The Shapiro–Wilk normality test was applied to assess the normality of data distribution. Data
from HCM and CTRL were analyzed by t-test and correlation between clinical and experimental
variables by Spearman test. p Values < 0.05 were considered significant. Prism 8.2 was used.
3. Results
3.1. Study Population
Seventeen HCM patients were enrolled. Baseline clinical and echocardiographic data are
summarized in Tables 1 and 2, respectively.
Table 1. Baseline characteristics of hypertrophic cardiomyopathy (HCM) patients.
Demographic Data N = 17
Age (years), M (SD) 59 (9)
Gender (male), N (%) 12 (70)
BMI (kg/m2), M (SD) 28 (5)
Clinical data
Positive genetic screening, N (%) 6 (35)
VUS N (%) 3 (17.5)
Family history of HCM, N (%) 5 (29)
Family history of SCD, N (%) 3 (18)
NYHA ≥ III, N (%) 6 (35)
Angina, N (%) 1 (6)
Syncope, N (%) 2 (12)
Atrial fibrillation (previous history), N (%) 3 (18)
NSVT, N (%) 1 (6)
Medical Therapy
Beta-blockers, N (%) 14 (82)
Antiarrhythmic drugs, N (%) 4 (23)
Diuretics, N (%) 13 (76)
RAAS-i, N (%) 10 (59)
M, mean; SD, standard deviation; N, number; %, percentage; BMI, body mass index; VUS, Variants of uncertain
significance; SCD, sudden cardiac death; NYHA, New York Heart Association class; NSVT, nonsustained ventricular
tachycardia; RAAS-i, renin-angiotensin-aldosterone system inhibitors.
Table 2. Echocardiographic data of HCM patients.
Echocardiographic Structural Data
IVS thickness (mm), M (SD) 20 (5)
PW thickness (mm), M (SD) 14 (3)
IVS/PW ratio, M (SD) 1.5 (0.3)
LV- EDD (mm), M (SD) 45 (7)
LA volume (cc), M (SD) 88 (38)
Systolic function
LV-EF (%), M (SD) 63 (6)
TDI s’ peak (cm/sec), M (SD) 9 (1)
Diastolic function
E peak (cm/sec), M (SD) 56 (25)
A peak (cm/sec), M (SD) 67 (26)
E/A ratio, M (SD) 1.0 (0.8)
DT (ms), M (SD) 153 (55)
IVRT (ms), M (SD) 78 (20)
TDI e’ peak (cm/sec), M (SD) 10 (2)
TDI, a’ peak (cm/sec), M (SD) 12 (4)
E/e’ ratio 7 (4)




PAPs (mmHg), M (SD) 33 (7)
SAM-related LVOT-max gradient at rest (mmHg), M (SD) 76 (30)
Moderate-to-severe mitral regurgitation, N (%) 7 (41)
M, mean; SD, standard deviation; N, number; %, percentage; IVS, interventricular septum; PW, posterior wall; LV,
left ventricular; EDD, end diastolic diameter, LA, left atrial; EF, ejection fraction; TDI, tissue Doppler imaging; s,
systolic; E, early filling velocity; A, atrial contraction velocity; DT, deceleration time; IVRT, iso-volumetric relaxation
time; PAPs: pulmonary arterial pressure; Max, maximum; LVOT, left ventricular outflow tract.
Histologic evaluation of myectomies showed features consistent with the clinical diagnosis of
HCM in all cases (Supplementary Figure S3). Eight CTRL biopsies were collected and histology showed
normal myocardial structure. Due to privacy law, no data about donors were available.
Mutations were demonstrated in 35% of HCM patients (Table 3).
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MYH7 c.428G>A p.(Arg143Gln) missense Homburger et al. PNAS,2016
Class 4-Likely
pathogenic




* Sequence variant nomenclature based on Human Genome Variation Society nomenclature (HGVS), ** Human
Gene Mutation Database (HGMD®) represents an attempt to collate all known (published) gene lesions responsible
for human inherited disease, *** sequence variant classification based on American College of Medical Genetics and
Genomics (ACMG) guidelines.
3.2. OXPHOS: Expression and Activity of Complex I and Complex V
To investigate potential changes in mitochondrial activity between HCM and CTRL, two enzymatic
complexes at the extremes of the OXPHOS respiratory chain were analyzed.
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A higher amount of NADH dehydrogenase, i.e., Complex I, (p = 0.0297) was detected in whole
extracts from HCM (Figure 1A). Semiquantitative analysis of NADH dehydrogenase histochemistry
showed a stronger signal (p = 0.0065) in HCM, but a comparable localization: the signal was intense in
cardiomyocytes, weak in vessels, and absent in the interstitium (Figure 1B). Isolated mitochondria
demonstrated a significant increase of Complex I activity in HCM (Figure 1C, p < 0.0001).
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Figure 1. OXPHOS complexes I and V and ATP synthesis. Quantification of NADH dehydrogenase protein
amount in myocardial tissue from 17 HCM and seven control (CTRL) samples is shown. (A) Representative
images of NADH dehydrogenase histochemistry on myocardial cryosections are shown ((B), left panels).
Blue formazan inte s y indic tes NADH en yme activi y in cryosections. Semiquantitative evaluation of
formazan signal optical density in 10 HCM and six CTRL chosen randomly is presented ((B), right graph).
Kinetics of Complex I activity (i.e., oxidized NADH) in tissue-isolated mitochondria (C) are plotted. Mean
optical density values/group ±SEM (17 HCM and 7 CTRL samples) are shown for absorbance read every
1 min. The double arrow indicates the differe ce between the parallel curves at the end of the measure.
Quantitative evaluations of ATP sy thase amount ((D), left graph) and kinetics ((D), right graph) are shown
(16 HCM, seven CTRL, three replicates/sample). In ((D), right graph), mean optical density values/group
±SEM are shown for absorbance read every 45 s. Double arrow indicates the difference between the
fit curves for HCM and CTRL at the end of the measure. Quantification of ATP amount in a subset of
myocardial tissues (eight HCM and five CTRL sample ) is plotted (E). U paired t- est is applied. Data in
(A) left, ((B,D), left) and (E) are presented in boxes (min to max) and dots indicate single sample values
(mean values from three replicates). Dark blue dots indicate HCM patients with mutation, light blue dots
those without. Significant differences are shown as * p < 0.05.
ATP synthase, i.e., Complex V, level was comparable in whole extracts from HCM and CTRL, and
only a trend towards decreased activity was found in HCM (Figure 1D). The amount of myocardial ATP
was increased (p = 0. 492) in HCM (Figure 1E), but the amount of CK-MB was comparable between
HCM and CTRL (Supplementary Figure S4).
3.3. Mitochondria: Enzymatic Scavengers and DNA Copy Number
The determination of ROS scavengers demonstrated no difference for intracellular Cu/Zn-activated
superoxide dismutase (SOD1) activity in HCM vs. CTRL (Figure 2A) while mitochondrial Mn-activated
superoxide dismutase (SOD2) (Figure 2B) was significantly higher in HCM (p = 0.0069). Furthermore, a
significant increase in mitochondrial (m-)aconitase activity was found in HCM (p = 0.0143, Figure 2C). No
difference in mitochondrial DNA (mtDNA) copy number was found between HCM and CTRL (Figure 2D).
3.4. ATPases
The interplay between ROS, ATP, and Ca2+-activated ATPase has been described [9]. Ca2+-activated
ATPase hydrolytic activity was comparable in HCM and CTRL (Figure 3A). ATPase histochemistry
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showed the fast and slow enzymatic activities in cardiomyocyte bundles and in vessels (Figure 3B),
without any difference between HCM and CTRL. The amount of ATP2A2 (SERCA2, slow, Figure 3C)
was higher than that of ATP2A1 (SERCA1, fast, Figure 3D) without a significant difference between
HCM and CTRL. However, an increased ATP2A2/ATP2A1 ratio was found in HCM (p = 0.0404,
Figure 3E), indicating a tendency of slow ATPase to prevail.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 8 of 14 
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Figure 2. Reactive oxygen species (ROS) scavenging enzymes’ activity and mtDNA quantification of
SOD1 (A), SOD2 (B) and (m-)aconitase (C) activities in tissue extracts are plotted, showing high activity of
SOD1 in both groups, and the activation of SOD2 and (m)-aconitase in HCM. The absence of difference
between HCM and CTRL in total mtDNA copy number into myocardial tissue is displayed (D). Data from
17 HCM and seven CTRL samples are presented as boxes ( in to max) and dots indicate single sample
values (mean values from three replicates). Dark blue dots indicate HCM patients with mutation, light
blue dots those without. Unpaired t-test is applied. Significant differences are shown as * p < 0.05 and
** p < 0.01.
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Figure 3. Ca2+-activated ATPases. Quantification of Pi from ATP hydrolysis by Ca2+-activated ATPase
in myocardial tissue extracts enriched for myosins is plotted. (A) Left atrium from a donor heart and
skeletal muscle extracts are used as technical controls. Representative histochemistry images showing the
homogeneous distribution of active fast and slow ATPase on cryosections from HCM and CTRL are shown
(B). Notice the absence of difference in the brown signal intensity, irrespective of the presence of disarray
in the HCM field. Tissue contents of fast (ATP2A1, (C)) and slow (ATP2A2, (D)) ATPase and their ratio
measured by ELISA in extracts from HCM (n = 17) and CTRL (n = 8) are shown (E). D ta are presented as
boxes (min to max) and dots indicate single sample values. Dark blue dots indicate HCM patients with
mutation, light blue dots those without. Mann–Whitney test was applied and significant difference is
shown as * p < 0.05.
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4. Discussion
The present study demonstrates changes in OXPHOS and ROS scavenger activities in HCM
myocardium and a switch from fast to slow Ca2+-activated ATPase compared to CTRL.
Mechanoenergetic uncoupling may play a central pathogenetic role and positron electron
tomography (PET) showed that regional work rate of the LV was comparable [32,33]. PET also
revealed reduced glucose metabolism but augmented free fatty acid uptake in the hypertrophied
septum, and, as free fatty acids give a less energy-efficient fuel, this may contribute to reduced
mechanical efficiency [32,33]. Previous papers based on myectomy samples from patients with
obstructive HCM [34] have shown that the overarching molecular and energetic features of the disease
are comparable and consistent among individuals with different pathogenic mutations in different
genes [31]. Phosphorus magnetic spectroscopy showed impaired energy metabolism, demonstrated
by reduced PCr/ATP in patients with HCM-harboring mutations in the genes for either β-myosin
heavy chain, cardiac troponin T, or MyBPC3, as compared to controls [6]. A mismatch between energy
demand and supply has been suggested using 31Phosphorus magnetic spectroscopy demonstrated a
significant (20%) reduction in resting [PCr]/ATP ratio in HCM patients vs. healthy volunteers, related
to the degree of diastolic dysfunction, but not to the degree of hypertrophy, perfusion reserve, or
patchy fibrosis [35].
Variability in mitochondrial organization, number, and size was associated with impairment of
myocardial contractile and lusitropic reserve in HCM [11]. Impaired cardiac OXPHOS with increased
ROS production and enhanced oxidative stress have been described in isolated cardiac muscles and
mitochondria from domestic cats with spontaneously occurring HCM [36,37]. Increased Ca2+sensitivity
of ATPase rate with modification of myofilament proteins was found in Tm-E180G mutant
mice [36,37]. Oxidative stress, studied immunohistochemically as expression of 4-hydroxy-2-nonenal
(HNE)-modified protein, a major lipid peroxidation product, was elevated in septal biopsy samples
from nongenetically profiled patients with HCM compared with control subjects [12]. In line
with an increased ROS production, we found that NADH dehydrogenase was increased in both
quantity and activity. The latter was counteracted by increased activity of (m-)aconitase, a ROS
sensor [38] and mtDNA stabilizer [39], and of antioxidant mitochondrial SOD2 [40]. Conversely,
there was no increase in SOD1, another ROS scavenger, suggesting a minor role for this enzyme
similarly to human dilated cardiomyopathy [41]. These findings are at odd with those obtained
acutely in mice, and human end-stage heart failure (HF). In mice, SOD attenuation was observed in
isoproterenol-induced hypertrophy. [42]. Discrepant findings were found in human end-stage HF
due to DCM or ischemic cardiomyopathy. In vitro and ex vivo studies showed low (m-)aconitase and
SOD2 activities, supporting the oxidative injury as a major determinant of cardiomyocyte dysfunction
at post-translational level [43,44]. Conversely, other authors observed upregulated catalase but
no difference in SOD isoforms in association to abnormal mitochondrial respiration) [45] or the
upregulated SOD2 gene, but downregulated protein activity [46]. As mtDNA is vulnerable to ROS [47],
the preservation of mtDNA copy number speaks in favor of ROS quenching by mitochondria in HCM.
HF can be the consequence of a broad spectrum of different clinical conditions with diverse
pathophysiology, which might explain these discrepancies. While classic models of HF are characterized
by reduced ejection fraction, HCM is a paradigm of diastolic dysfunction with normal or even
super-normal myocardial contractility. Consequently, any a priori assumption that the conclusions
of prior studies on HF might be extended to HCM would have been arbitrary [4]. This is why we
embarked on the present investigation. The issue of whether the reversal of HF symptoms, observed in
>90% of HCM patients undergoing surgical septal myectomy [48] is at least in part related to changes
in oxidant/antioxidant enzymes remains to be elucidated.
The novelty of our data on mitochondria resides in the demonstration of the activation of both pro-
and anti-ROS mechanisms in HCM, possibly representing an adaptive response, aimed at restraining
oxidative stress and energetic loss. These data also underline the intricate balance between ROS
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generation/scavenging and energy metabolism suggesting a mechanistic difference in the energetic
impairment between end-stage HF and HCM.
Although we cannot exclude ATP recovery in the harvested tissues, the absence of decline in ATP
level is in agreement with data in patients with LV hypertrophy secondary to arterial hypertension [49],
with previous studies in isolated beating rat hearts in conditions of pressure overload [50], and with
the paradigm of inefficient energy usage downstream mitochondria [8]. An altered distance between
mitochondria and myofibrils has been reported in several HCM patients [11], representing a possible
obstacle for ATP to reach its consumption sites.
Coupling between mitochondria and contractile apparatus or intracellular stores, i.e.,
sarcoendoplasmic reticulum and myofilaments, involves Ca2+-activated ATPases [51,52]. Whether the
latter may adapt to mitochondrial changes by activating mechanisms preserving myocardial function
remains to be elucidated. Decreased ATP2A2 (SERCA2) was associated to reduced Ca2+ uptake by
sarcoplasmic reticulum of cardiomyocytes both in experimental models and patients with HF [53].
Increased ATP2A2 activity ameliorated contractility through normalizing the PCr/ATP ratio in animal
models of HF (16) and gene transfer to failing rat hearts improved myocardial energetics [54]. The
observed switch from fast ATP2A1 to slow ATP2A2 might be finalized at decreasing ATP requirement
while maintaining Ca++ re-uptake into the endoplasmic reticulum and cell contractility.
Limitations
We acknowledge several limitations in this proof-of-concept study. We cannot rule out that
differences in tissue collection and processing between patients and controls might have affected, at
least in part, the results, although similar methods were used previously, supporting the feasibility of
enzymatic studies on bioptic samples [55]. Studies of oxidative stress have advanced our understanding
of basic mechanisms of disease in the failing heart. Yet, in the two decades since the seminal paper by
Dieterich et al, important gaps remain unaddressed, mainly due to the inherent challenges of collecting
large series of human myocardial samples and technical difficulties. The ex vivo investigation of
human myocardium provides a snapshot of the tissue condition, where most of the enzyme activities
are preserved in carefully harvested samples, but highly unstable byproducts such as ROS are difficult
to assess. ATP can be measured only within a short time from sample collection and absolute
values could be affected by ATP pool replenishment, comparable both in pathological and normal
samples (supported by CK-MB activity, similar in both). Any further assessment of the switch from
ATP2A1 to ATP2A2 will require a dedicated study by a high-sensitivity proteomic method such as
mass spectrometry.
The absence of a relationship between results and patients’ genetic profile may be due, at least in
part, to the limited proportion of patients with identified mutation in our HCM cohort. Analyzing
individual genotypes separately to identify potential—but likely minor—differences in the molecular
and energetic features of the disease would be interesting. However, this would be hardly feasible given
the practical implications related to obtaining an adequate number of homogeneous surgical samples.
The results of the present apply to only to obstructive HCM. Similar studies in nonobstructive
HCM are not feasible due to lack of surgical indications.
5. Conclusions
This study demonstrates hyperactivity of several myocardial mitochondria enzymes in HCM,
suggestive of inefficient energy usage downstream the organelles rather than insufficient supply. The
myocardial switch towards slow-twitch Ca2+-activated ATPase, more economical in terms of ATP
consumption, further supports the defective energy utilization hypothesis of HCM [56].
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